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Summary
Background Clinical guidelines suggest preventive interventions such as statin therapy for individuals with a high 
estimated 10-year risk of major cardiovascular events. For those with a low or intermediate estimated risk, risk-factor 
screenings are recommended at 5-year intervals; this interval is based on expert opinion rather than on direct research 
evidence. Using longitudinal data on the progression of cardiovascular disease risk over time, we compared different 
screening intervals in terms of timely detection of high-risk individuals, cardiovascular events prevented, and health-
care costs.
Methods We used data from participants in the British Whitehall II study (aged 40–64 years at baseline) who had 
repeated biomedical screenings at 5-year intervals and linked these data to electronic health records between baseline 
(Aug 7, 1991, to May 10, 1993) and June 30, 2015. We estimated participants’ 10-year risk of a major cardiovascular 
event (myocardial infarction, cardiac death, and fatal or non-fatal stroke) using the revised Atherosclerotic 
Cardiovascular Disease (ASCVD) calculator. We used multistate Markov modelling to estimate optimum screening 
intervals on the basis of progression rates from low-risk and intermediate-risk categories to the high-risk category 
(ie, ≥7·5% 10-year risk of a major cardiovascular event). Our assessment criteria included person-years spent in a 
high-risk category before detection, the number of major cardiovascular events prevented and quality-adjusted life-
years (QALYs) gained, and screening costs.
Findings Of 6964 participants (mean age 50·0 years [SD 6·0] at baseline) with 152 700 person-years of follow-up (mean 
follow-up 22·0 years [SD 5·0]), 1686 participants progressed to the high-risk category and 617 had a major 
cardiovascular event. With the 5-year screening intervals, participants spent 7866 (95% CI 7130–8658) person-years 
unrecognised in the high-risk group. For individuals in the low, intermediate-low, and intermediate-high risk 
categories, 21 alternative risk category-based screening intervals outperformed the 5-yearly screening protocol. 
Screening intervals at 7 years, 4 years, and 1 year for those in the low, intermediate-low, and intermediate-high-risk 
category would reduce the number of person-years spent unrecognised in the high-risk group by 62% (95% CI 57–66; 
4894 person-years), reduce the number of major cardiovascular events by 8% (7–9; 49 events), and raise 44 QALYs 
(40–49) for the study population.
Interpretation In terms of timely preventive interventions, the 5-year screening intervals were unnecessarily frequent 
for low-risk individuals and insufficiently frequent for intermediate-risk individuals. Screening intervals based on 
risk-category-specific progression rates would perform better in terms of preventing major cardiovascular disease 
events and improving cost-effectiveness.
Funding Medical Research Council, British Heart Association, National Institutes on Aging, NordForsk, Academy of 
Finland.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Many national and international guidelines for primary 
prevention of cardiovascular disease recommend the 
estimated risk of a major cardiovascular event as the best 
guide to intervention decisions.1–6 The 2016 European 
guidelines suggest screening every 5 years for men older 
than 40 years and women older than 50 years,2 whereas 
the 2013 American Heart Association/American College 
of Cardiologists (AHA/ACC) guidelines5 recommend 
screening at 4–6-year intervals for individuals without 
cardiovascular disease whose 10-year risk of a major 
cardiovascular event is lower than 7·5%, as calculated 
with the Atherosclerotic Cardiovascular Disease (ASCVD) 
algorithm. After the risk reaches 7·5%, the AHA/ACC 
guidelines5 classify individuals as being at high risk and 
recommend implementation of pre ventive interventions 
and more frequent risk-factor assessments. A 2018 
New Zealand Guideline recom mends risk-category-
specific 10-year, 5-year, and 2-year screening intervals for 
low-risk, intermediate-low-risk, and intermediate-high-
risk individuals for a composite outcome of hospital-
isation or death from ischaemic heart disease (including 
unstable angina), stroke, transient ischaemic attack, 
heart failure, or peripheral vascular disease.1 However, 
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none of these screening intervals are based on observed 
cardiovascular disease risk progression. Instead, they 
stem mainly from expert opinion.6
The 2015 PESA study7 revealed substantial differences 
in subclinical atherosclerosis among individuals with 
estimated risk of major cardiovascular events lower than 
7·5% according to the ASCVD algorithm. General 
subclinical atherosclerosis occurred at four to six sites in 
8% of participants whose estimated risk was lower than 
5·0%, and in 24% of those whose estimated risk was 
5·0–7·5%. Only 44% and 21% of individuals, respectively, 
in these two categories were completely free of athero-
sclerosis. Because the degree of atherosclerosis varies 
among individuals below the ASCVD 7·5% risk threshold, 
a uniform 5-year screening interval might not be optimal 
for everyone in the low-risk and intermediate-risk 
categories. However, evidence for the 10-year progression 
of risk of a major cardiovascular event at the population 
level in those risk categories remains scarce.2,4,5
In this prospective cohort study, we used a revised 
version of the ASCVD algorithm to estimate distributions 
of progression times from low-risk and intermediate-risk 
categories to the high-risk category of a major cardio-
vascular event (defined as myocardial infarction, death 
from coronary heart disease, or fatal or non-fatal stroke). 
The high-risk category is the threshold for considering 
preventive medication such as statin therapy. On the 
basis of these estimates, we sought to establish an 
optimal screening protocol for low-risk and intermediate-
risk individuals and compared it with the current 
recommendation of 5-yearly screenings2,4,5 in terms of 
timely detection of high-risk individuals, major cardio-
vascular events prevented, quality-adjusted life-years 
(QALYs) gained, and costs.
Methods
Study design and participants
We used data from the British Whitehall II cohort 
study.8 In 1985, all civil servants aged 35–55 years and 
working in 20 government departments in London, UK, 
were invited by letter to participate; 10 308 (73%) of 
14 121 agreed. The clinical examination at study entry 
between Sept 10, 1985, and March 29, 1988, did not 
include all cardio vascular risk factors. Participants under-
went clinical examinations for a comprehensive set of 
risk factors in line with European, British, and US 
guidelines at 5-year intervals2,4,5 between Aug 7, 1991, and 
May 10, 1993; April 24, 1997, and Jan 8, 1999; Oct 8, 2002, 
and Sept 10, 2004; Oct 10, 2007, and Nov 18, 2009; 
and Jan 27, 2012, and Oct 30, 2013.
The baseline for this study was Aug 7, 1991, to 
May 10, 1993 (the first com prehensive risk factor 
screening), and participants were eligible for the present 
analysis if they had participated in at least two risk-factor 
Research in context
Evidence before this study
Screening for cardiovascular disease risk factors allows detection 
of high-risk individuals and determination of initiation of 
preventive interventions such as statin therapy, but optimal 
screening intervals for people with low or intermediate 
cardiovascular risk remain unclear. We searched PubMed for 
current cardiovascular disease risk-estimation guidelines and their 
screening recommendations on Sept 30, 2018, using the Medical 
Subject Headings search terms “myocardial infarct”, “stroke”, 
“guideline”, and “risk assessment”. Many primary prevention 
guidelines recommend use of estimated 10-year risk of major 
cardiovascular events to guide initiation of interventions and 
screening decisions. The most common recommendation was 
5-yearly screening for all individuals at low or intermediate risk, 
although other screening intervals, such as 10-yearly and 2-yearly 
screenings, were also recommended. These intervals were expert 
recommendations rather than based on evidence from observed 
cardiovascular disease risk progression.
Added value of this study
According to this observational study using repeat data from 
6964 middle-aged British men and women, the average 
progression time from the categories of low or intermediate risk 
of a major cardiovascular event to the high-risk category 
(ie, ≥7·5% 10-year risk of a major cardiovascular event) depends 
on the initial risk category. In terms of timely initiation of 
intensified preventive interventions when the high-risk category 
is achieved, 5-yearly screening was unnecessarily frequent for 
low-risk individuals and insufficiently frequent for 
intermediate-risk individuals. We estimate that, on the basis of 
observed progression of major cardiovascular event risk, 
risk-category-specific screening intervals are more optimum than 
is the 5-yearly interval. For example, 7-year, 4-year, and 1-year 
screening intervals for low-risk, intermediate-low-risk, 
and intermediate-high-risk individuals would reduce the number 
of person-years spent unrecognised in the high-risk group and 
prevent major cardiovascular events without increasing costs. 
In terms of major cardiovascular events prevented and 
quality-adjusted life-years gained, 21 other screening intervals 
based on initial estimated risk category were also better than 
the uniform 5-yearly screening for everyone.
Implications of all the available evidence
Compared with the uniform 5-yearly screening strategy, 
screening intervals based on risk category were estimated to 
prevent a larger proportion of major cardiovascular events, 
to increase quality-adjusted life-years, and to reduce 
health-care costs. These findings suggest that one size fits all is 
not an optimum screening approach and support a change 
from uniform screening intervals to ones that are dependent 
on the estimated level of risk. Further research is necessary to 
assess the generalisability of our findings and to evaluate the 
benefits and costs in relation to lifetime risk rather than 
to 10-year estimated risk.
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screenings between this period and Jan 27, 2012, to 
Oct 30, 2013, or had participated in one screening and 
had a major cardiovascular event or died during follow-
up. We excluded people with evidence of stroke, 
myocardial infarction, heart failure, atrial fibrillation, 
coronary artery bypass graft, or percutaneous coronary 
intervention at baseline.
At each examination, participants provided written 
informed consent for inclusion. Research ethics approval 
was granted by the University College London Hospital 
Committee on the Ethics of Human Research.
Procedures
Data on age and smoking were collected with standard 
self-administered questionnaires. Experienced clinical 
nurses measured height, weight, and systolic and 
diastolic blood pressure, and took blood samples for lipid 
and glucose measurements.8 Diabetes was defined as a 
fasting glucose concentration of at least 7 mmol/L or use 
of an antidiabetic drug. Additionally, participants brought 
all their medication to the clinical examination and thus 
pro vided information on their use of statins, anticoagu-
lants, and antihypertensives.
We calculated the ASCVD estimator recommended by 
the AHA/ACC guidelines on the basis of the following 
variables: age, sex, total cholesterol, HDL cholesterol, 
systolic blood pressure, antihypertensive medication (yes 
or no), smoking (yes or no), and diabetes (yes or no).5
Major cardiovascular events were defined as fatal coro-
nary heart disease, non-fatal myocardial infarction, and 
fatal or non-fatal stroke. 10 297 (>99%) of 10 308 partici-
pants in the British Whitehall II cohort study were traced 
successfully and have been followed up for mortality 
through the national mortality register kept by the 
National Health Service (NHS) Central Registry, which 
provides information on the date and cause of each 
death. Coronary heart disease mortality was defined by 
International Classification of Diseases (ICD)-9 codes 
410–414 or ICD-10 codes I20–25 and stroke mortality by 
ICD-9 codes 430–438 or ICD-10 codes I60–69.
Non-fatal myocardial infarction was defined following 
the WHO multinational monitoring of trends and deter-
minants in cardiovascular disease (MONICA) criteria 
based on British Whitehall II cohort study electro-
cardiograms, hospital acute electrocardiograms, and 
cardiac enzymes, and was validated by means of discharge 
diagnoses from NHS Hospital Episode Statistics (HES; 
ICD-10 code I21) data or general practitioner confir-
mation.9 Classification was done independently by two 
trained coders (Whitehall II personnel), with adjudication 
in the event of disagreement.
Ascertainment for non-fatal stroke was based on self-
reported diagnosis and use of the MONICA-Augsburg 
stroke questionnaires that capture symptoms associated 
with events, even if the participant did not report having 
had a diagnosis. If a participant responded positively to at 
least one of these questionnaires, their histories were 
corroborated with the general practitioner’s confirmation, 
HES data linkage, or manual retrieval of hospital medical 
records reviewed by a stroke clinician.10 The ICD-codes 
used for stroke ascertainment were ICD-9 430, 431, 434, 
and 436, and ICD-10 I60, I61, I63, and I64.
Participants were followed up until incident myocardial 
infarction, stroke, death, or June 30, 2015 (the date on 
which cleared outcome data on major cardiovascular 
events were available), whichever came first. In previous 
validation analyses, the estimates of associations between 
cardiovascular risk factors and major cardiovascular 
events were similar for MONICA and electronic health-
record-based ascertainment methods.9
Statistical analysis
First, we assessed whether the ASCVD calculator showed 
appropriate discrimination and absolute risk estimation 
in this population. The algorithm showed good dis-
crimination, but it overestimated the absolute risk in this 
population (appendix pp 1–6).5 This overestimation is 
expected because prevalence of risk factors, access to 
and compliance with treatments, and incidence of 
cardiovascular disease occur at more favourable levels in 
occupational cohorts relative to the general population 
(known as the healthy-worker effect).11 We therefore 
revised the ASCVD calculator and used this revised 
version to estimate the 10-year risk of a major cardio-
vascular event at each of the five clinical screenings. In 
the revision, we used the Cox proportional hazards 
model,12 the same variables, and the same protocol that 
were used in derivation of the original ASCVD calculator.5 
After this revision, the calculator did not overestimate 
10-year risk of major cardiovascular disease events and 
had Harrell’s C index of 0·72 (appendix pp 1–6).
We used multistate Markov models to model risk 
progression across the revised ASCVD risk categories. 
Multistate Markov models, which are useful for 
modelling progression of chronic disease risk in medical 
re search,13–17 are based on data from repeated individual-
level measurements and from a transition matrix that 
estimates changes, both adverse and favourable, in risk 
category.18 These models allow the estimation of both 
progression and recovery in terms of risk categories and 
can be used to estimate the probability of change from 
one risk state to another and the percentage of individuals 
in each risk category after a certain time interval. A 
further useful feature of Markov models is that they 
allow outcomes, such as major cardiovascular events, 
and competing outcomes, such as death, that would end 
the follow-up at any time, to be incorporated into the 
modelling.
We used R package msm18 to model risk progression 
across risk categories (states in the multistate model), 
as defined by revised 10-year ASCVD-estimated risk 
of a major cardiovascular event: low (0 to <2·5%), 
intermediate-low (2·5 to <5·0%), intermediate-high 
(5·0 to <7·5%), and high risk (≥7·5%). We chose these 
See Online for appendix
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categories to represent progression towards the high-risk 
(7·5%) major cardiovascular event threshold at which 
consideration of treatment is recommended according to 
AHA/ACC guidelines.5
We modelled risk progression as snapshots in time, 
allowing both forward and backward transitions between 
risk categories over time, and we treated major cardio-
vascular events as an absorbing category (ie, no 
progression estimated thereafter) and death as a 
competing absorbing category. A transition intensity 
matrix derived from the multistate model provided 
transition probabilities and the average time spent in 
each category. In multistate models, we used the quasi 
Newton Broyden–Fletcher–Goldfarb–Shanno algorithm 
for optimisation18 and achieved the 1 × 10–¹⁶ convergence 
criteria. To evaluate convergence to anything other than 
10 308 participants assessed for eligibility
2826 excluded
 199 prevalent cardiovascular disease
 463 deaths
 2164 fewer than two measurements after 
  the baseline
518 new participants from study entry included
7482 met eligibility criteria
Eligible population at each clinical examination 
7482 met eligibility criteria
518 excluded
 383 non-attendance
 135 missing data
6964 participants assessed at baseline (1991–93)
2100 excluded
 174 incident major cardiovascular events 
 167 non-cardiovascular deaths
 254 non-attendance
 1505 missing data
1759 new participants from earlier examinations 
  included
7141 alive and without major cardiovascular events 5382 participants assessed at first follow-up (1997–99)
1231 excluded
 171 incident major cardiovascular events
    197 non-cardiovascular deaths
    497 non-attendance
    366 missing data
863 new participants from earlier examinations 
  included
6773 alive and without major cardiovascular events 5910 participants assessed at second follow-up (2002–04)
1262 excluded
 152 incident major cardiovascular events 
 167 non-cardiovascular deaths
 450 non-attendance
 493 missing data
943 new participants from earlier examinations 
  included
6454 alive and without major cardiovascular events 5511 participants assessed at third follow-up (2007–09)
6204 alive and without major cardiovascular events 4985 participants assessed at fourth follow-up (2012–13)
1469 excluded
 83 incident major cardiovascular events 
 167 non-cardiovascular deaths
 602 non-attendance
 617 missing data
Figure 1: Flow chart of sample selection at each clinical examination
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maximum likelihood, we ran our multistate model with 
variations in initial transition values, but the results were 
robust and remained unchanged (appendix pp 6–8). We 
did this assessment because in some cases the results of 
the multistate model can be sensitive to the choice of 
initial transition values.18
To derive optimal screening intervals, we defined the 
shortest possible screening interval to 1 year, which is 
used for high-risk individuals,5 but did not limit the 
longest possible screening interval. Because the 
AHA/ACC guideline recommends a more frequent 
screening interval for high-risk individuals,5 we did not 
allow backward transfer from high-risk category in the 
final model when deriving the optimal screening 
intervals. However, we allowed backward transition to 
show observed risk reduction, and in this sensitivity 
analysis the progression-time estimates did not change 
substantially. Comparison of the observed and ASCVD-
estimated numbers of individuals in each risk category 
showed that the multistate model fitted our data well 
(appendix pp 6–8). Additionally, the 10-year major 
cardiovascular event risk estimates derived from the 
multistate model and the revised ASCVD calculator 
using Cox regression were similar (appendix p 9).
We estimated the costs for an NHS health check as 
£5·11 per invitation and £13·28 per screening19 and 
assumed that successful statin treatment would save 
0·01 major cardiovascular events per person-year.20 We 
derived the cost-effectiveness and QALYs gained by statin 
treatment from the West of Scotland Coronary Pre vention 
Study (WOSCOPS),21 in which participants were randomly 
assigned to primary prevention with pravastatin or placebo, 
and comprehensive real-world and long-term follow-up 
data on all cardiovascular outcomes and all related costs 
were collected. We estimated the screening costs and 
QALYs gained per year for the population of England and 
Wales aged between 40 and 64 years (the same age range as 
in our cohort at baseline) by using the population estimates 
derived from the Office for National Statistics22 and 
10-year risk distributions for major cardiovascular events 
(estimated with the QRISK2 calculator) derived from the 
primary care population of England and Wales.23 The 
estimates of QALYs and costs reduced with prevention 
of major cardiovascular events are discounted with an 
annual discount factor of 3·5% as recommended by the 
UK treasury,21 whereas the screening costs were not 
discounted to avoid overestimation of benefits.
To explore whether selection bias might have occurred 
due to missing data, we undertook a sensitivity analysis 
in which we used multiple impu tation with chained 
equations based on the Nelson-Aalen estimator, on 
outcome data, on ethnic origin (white or non-white), and 
on repeated measurements of observed 10-year risk, 
socioeconomic status, alcohol consumption, physical 
activity, body-mass index, dietary approaches to stop 
hypertension (DASH) diet score, family history of 
myocardial infarction or stroke (in either parent or any 
sibling), and a general health questionnaire (with 
30 questions).
We imputed the data in wide form to take into account 
the clustering of repeated measurements within 
individuals. The diagnostics of our imputation model 
suggested that 10 iterations and 25 imputations were 
sufficient to produce reproducible results (appendix 
pp 14–16). The 25 datasets produced from imputations 
were then analysed separately with the multistate Markov 
models, and the results were combined using Rubin’s 
rules.24 This procedure takes into account the uncertainty 
in the imputation as well as uncertainty due to random 
variation. In these analyses, we examined whether 
the association of the revised ASCVD-estimated risk 
categories with incident major cardiovascular events in 
the imputed datasets (that aim to control potential 
selection bias) differed from the association in our main 
analysis that included missing data. All analyses were 
done with Stata version SE 14.2 and R version 3.4.3.
All (n=6964) Men (n=4866) Women (n=2098)
Baseline examination
Age, years 50·0 (6·0) 49·8 (6·0) 50·5 (6·1)
Systolic blood pressure, mm Hg 120·4 (13·5) 121·7 (13·1) 117·4 (13·9)
Total cholesterol, mmol/L 6·5 (1·1) 6·5 (1·1) 6·5 (1·2)
HDL cholesterol, mmol/L 1·4 (0·4) 1·3 (0·4) 1·7 (0·4)
Diabetes 137 (2%) 97 (2%) 40 (2%)
Current smoker 939 (13%) 601 (12%) 338 (16%)
Antihypertensive treatment 450 (6%) 265 (5%) 185 (9%)
10-year risk category at baseline
Original ASCVD
<2·5% (low) 2612 (38%) 1174 (24%) 1438 (69%)
2·5% to <5% (intermediate-low) 1857 (27%) 1403 (29%) 454 (22%)
5% to <7·5% (intermediate-high) 1024 (15%) 894 (18%) 130 (6%)
≥7·5% (high) 1471 (21%) 1395 (29%) 76 (4%)
Revised ASCVD
<2·5% (low) 3733 (54%) 2207 (45%) 1526 (73%)
2·5% to <5% (intermediate-low) 2119 (30%) 1713 (35%) 406 (19%)
5% to <7·5% (intermediate-high) 653 (9%) 547 (11%) 106 (5%)
≥7·5% (high) 459 (7%) 399 (8%) 60 (3%)
10-year risk category at fourth follow-up
Number of patients 4985 3581 1404
Original ASCVD
<2·5% (low) 51 (1%) 0 51 (4%)
2·5% to <5% (intermediate-low) 288 (6%) 18 (1%) 270 (19%)
5% to <7·5% (intermediate-high) 406 (8%) 163 (5%) 243 (17%)
≥7·5% (high) 4240 (85%) 3400 (95%) 840 (60%)
Revised ASCVD
<2·5% (low) 314 (6%) 92 (3%) 222 (16%)
2·5% to <5% (intermediate-low) 1377 (28%) 943 (26%) 434 (31%)
5% to <7·5% (intermediate-high) 1149 (23%) 846 (24%) 303 (22%)
≥7·5% (high) 2145 (43%) 1700 (47%) 445 (32%)
Data are mean (SD) or number (%). ASCVD=Atherosclerotic Cardiovascular Disease.
Table 1: Characteristics of the study population at baseline and at the last screening
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of this report. JVL and MK had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Our baseline cohort comprised 6964 participants 
(4866 men and 2098 women; figure 1) and provided 
152 700 person-years of follow-up. Mean age of the 
participants at baseline was 50·0 years (SD 6·0; table 1). 
The appendix (p 11) provides age distribu tions in each 
risk category by clinical examination. Antihypertensive, 
lipid-lowering, and anticoagulation medication use 
increased over the follow-up period, which is consistent 
with the increasing percentage of high-risk individuals 
over time (appendix p 6).
During a mean follow-up of 22·0 years (SD 5·0), 
1686 participants progressed to the high-risk category, 
617 had a major fatal or non-fatal cardiovascular event, 
and 788 died due to non-cardiovascular causes. The 
major cardiovascular events comprised 332 non-fatal 
myocardial infarctions, 71 coronary heart disease deaths, 
and 205 non-fatal and nine fatal strokes. Of 617 major 
cardiovascular events, 360 (58%) occurred in individuals 
at high risk and 257 (42%) occurred in those with low or 
intermediate risk at their most recent 5-year screening.
Time spent in each risk category ranged from a mean of 
8·7 years (95% CI 8·4–9·0) spent in the low-risk (<2·5%) 
category to 3·9 years (3·7–4·1) in the intermediate-high-
risk (5·0 to <7·5%) category (figure 2). The mean time 
spent before reaching the high-risk category was 
19·8 years (95% CI 19·4–20·3) for participants in 
the low-risk category, 11·1 years (10·7–11·5) in the 
intermediate-low-risk category, and 3·9 years (3·7–4·1) in 
the intermediate-high-risk category. Participants who 
reached the high-risk category spent a mean of 6·7 years 
(6·3–7·1) in this category, after which an estimated 42·7% 
(95% CI 39·5–45·8) showed a reduced risk and 47·2% 
(43·9–50·1) progressed to the very-high-risk category 
(≥15%), 4·5% (3·5–5·9) had a major cardiovascular event, 
and 5·6% (4·0–7·7) died from non-cardiovascular causes.
Participants from low-risk and intermediate-low-risk 
categories progressed towards higher risk categories 
more often than did those at high risk; the reverse 
transition was more common from the higher risk 
categories (figure 2). All factors in the ASCVD calculator 
predicted progression from a lower to a higher risk 
category, with the strongest predictors being smoking, 
diabetes, and systolic blood pressure (appendix p 12). 
Secular trends in risk factors suggested that individuals 
quitting smoking, reducing their systolic blood pressure 
and cholesterol, and increasing their HDL concentration 
contributed to transitions from a higher to a lower risk 
category (appendix pp 12–14).
Since the progression rate to the high-risk category 
varied depending on the initial risk category, the 
proportion of participants who progressed to the high-
risk category before the next screen in the 5-year 
screen ing interval also varied depending on risk category: 
133 (2%) of 6630 person observations in the low-risk, 
895 (12%) of 7462 in the intermediate-low-risk, and 
1588 (45%) of 3528 in the intermediate-high-risk category 
progressed to the high-risk category before the next 
screen.
Of the 21 alternative risk-category-based screening 
interval protocols, 16 were associated with costs lower 
than or equal to those for the 5-year screening interval 
(figure 3). All 21 alternative models of risk-category-
specific screening intervals outperformed the uniform 
5-year screening interval in terms of person-years spent 
unrecognised in the high-risk category, QALYs gained, 
and major cardiovascular events prevented.
Figure 2: Estimated mean time spent in each major cardiovascular event 10-year-risk category and transition probabilities to the next risk category, 
incident major cardiovascular event (fatal or non-fatal) and non-cardiovascular death
Transition probabilities between groups and to events or deaths are presented next to arrows as percentage (95% CI). Mean time spent is calculated on the basis of all 
transitions and includes all individuals who visited the category during follow-up. The high-risk category has been split into two: high risk (7·5 to <15·0%) and very 
high risk (≥15%) to describe risk progression.
Low risk 
(<2·5%)
Mean time spent:
8·7 (8·4–9·0) years
Major
cardiovascular
event
Non-
cardiovascular
death
98·5%
(97·6–98·9)
0·6% (0·3–1·1)
1·0% (0·6–1·6)
1·6% (1·1–2·2)
1·8% (1·3–2·6)
1·9% (1·3–2·6)
1·5% (0·8–2·8)
4·5% (3·5–5·9)
47·5% (43·9–50·1)
5·6% (4·0–7·7)
Intermediate-low risk 
(2·5% to <5·0%)
Mean time spent:
7·2 (7·0–7·5) years
Intermediate-high risk
(5·0% to <7·5%)
Mean time spent:
3·9 (3·7–4·1) years
High risk
(7·5% to <15·0%)
Mean time spent:
6·7 (6·3–7·1) years
Major
cardiovascular
event
Non-
cardiovascular
death
Major
cardiovascular
event
Non-
cardiovascular
death
Major
cardiovascular
event
Very high risk
(≥15·0%)
Non-
cardiovascular
death
86·2%
(84·7–87·5)
72·9%
(70·6–74·7)
10·3%
(9·2–11·5)
23·8%
(22·0–25·7)
42·7%
(39·5–45·8)
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On the basis of progression rates to high risk from 
each risk category, we estimated the most optimal risk-
category-specific screening intervals that would not 
elevate health-care cost but would lead to more timely 
detection of high-risk individuals and a greater number 
of major cardiovascular events prevented and QALYs 
gained. The protocol was 7-year, 4-year, and 1-year 
screening intervals for low-risk, intermediate-low-risk, 
and intermediate-high-risk individuals, respectively 
(figure 3; appendix p 10).
Compared with 5-year screenings, screenings using 
7-year, 4-year, and 1-year intervals would reduce person-
years spent unidentified in the high-risk category by 
62% (95% CI 57–66; 4894 person-years). It would thus 
prevent an estimated 8% (95% CI 7–9; 49 events) of 
major cardiovascular events with earlier statin inter-
vention over the 20 years of follow-up and reduce the 
percentage of major cardiovascular events originating in 
the low-risk and intermediate-risk groups from 42% to 
34% (figure 3; table 2). With screening intervals at 
10, 5, and 2 years for low-risk, low-intermediate-risk, and 
high-intermediate-risk categories, the corresponding 
estimated reductions were 32% (29–36; 2527 person-
years) and 4% (3–5; 25 major cardiovascular events), 
respectively. The percentage of major cardiovascular 
events originating from low-risk and intermediate-risk 
groups would reduce from 42% to 38%.
Table 3 presents the estimated screening costs and 
person-years spent in the high-risk category with risk-
category-based screening intervals when compared with 
5-year screening intervals for the current population 
of England and Wales aged 40–64 years at baseline. 
After taking into account the extra mea surement costs 
and cardiovascular-disease-related costs saved with 
preventive statin medication, the 7-4-1 screen ing protocol 
for individuals in England and Wales would lead to 
savings of approximately £1 200 000 per year (95% CI 
900 000–1 400 000), 4564 QALYs (4163–4635) gained, and 
5034 major cardiovascular events (4592–5503) prevented 
per year compared with results with standard 5-year 
screening intervals. The benefits for the 10-5-2-year 
screening would be approximately £15 100 000 (95% CI 
14 200 000–16 100 000) in cost savings, 2475 QALYs 
(2219–2750) gained, and 2730 major cardiovascular 
events (2447–3033) prevented per year. Because of more 
person-years spent under statin treatment, both the 
7-4-1 and 10-5-2 screening protocols would be associated 
with a higher number of statin-related adverse events 
Figure 3: Comparison of 21 risk-category-specific screening intervals with the uniform 5-year screening interval
(A) Person-years spent unrecognised in high-risk category, (B) number of major cardiovascular events prevented, (C) difference in health-care costs, and (D) QALYs gained in the study population over 
the time of 20 years. The screening intervals are in years for those in low-risk, intermediate-low-risk, and intermediate-high-risk categories. Data are estimates with 95% CIs. QALY=quality-adjusted 
life-year.
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than would the 5-yearly screening (table 3). However, 
compared with the reduction in major cardiovascular 
events, the number of adverse events would be small 
(table 3).
Our sensitivity analysis with imputed missing data 
provided similar associations to those from our main 
analysis that used complete cases only (appendix 
pp 14–16).
Discussion
In this prospective longitudinal study, we found that risk 
progression accelerated with higher risk levels, suggesting 
that uniform 5-year screening intervals for low-risk, 
intermediate-low-risk, and intermediate-high-risk catego-
ries (as defined according to a revised ASCVD calculator) 
leads to unnecessarily long delays in detection of high-
risk individuals. Compared with the uniform 5-year 
5-5-5 screening interval* 10-5-2 screening interval* 7-4-1 screening interval*
Number of people at low or intermediate risk at baseline 6545 6545 6545
Number of person-years spent unidentified in high-risk category 7866 (7130 to 8658) 5339 (4885 to 5827) 2973 (2681 to 3292)
Difference in person-years spent unidentified in high-risk category 0 (reference) –2527 (–2831 to –2245) –4894 (–5366 to –4449)
Number of major cardiovascular events prevented 0 (reference) 25 (22 to 28) 49 (44 to 54)
Number of adverse events caused across the study period
Diabetes 0 (reference) 3·79 (3·37 to 4·25) 7·34 (6·67 to 8·05)
Haemorrhagic stroke 0 (reference) 0·38 (0·34 to 0·42) 0·73 (0·67 to 0·80)
Myopathy 0 (reference) 0·25 (0·22 to 0·28) 0·49 (0·44 to 0·54)
Number of QALYs gained 0 (reference) 23 (20 to 26) 44 (40 to 49)
Costs (thousands, £)†
Health-check costs 437 (428 to 445) 412 (400 to 425) 658 (627 to 693)
Costs saved owing to earlier prevention with statin 0 (reference) –120 (–134 to –106) –232 (–254 to –211)
Total costs (health-check costs – savings) 437 (428 to 445) 292 (291 to 294) 427 (416 to 439)
Total costs compared with 5-5-5 screening interval 0 (reference) –144 (–154 to –134) –10 (–12 to –7)
Data are estimate (95% CI), unless otherwise specified. Figures are estimated for a 20-year period. QALY=quality-adjusted life-year. *In years for low-risk, intermediate-low-risk, 
and intermediate-high-risk individuals (95% CI). †In the Whitehall II cohort of adults aged 40–64 years at baseline. Cost of £18·39 per health check derived from Kypridemos 
and colleagues19 and costs and QALYs gained with preventive statin treatment (£47·33 and 0·00906 QALYs gained per person-year under statin treatment compared with 
placebo) derived from Collins and colleagues20 and from the West of Scotland Coronary Prevention Study.21 The number of adverse events estimated based on incidence 
estimates of 0·0015, 0·00015, and 0·00010 for diabetes, haemorrhagic stroke, and myopathy20 among those who would have received statin treatment.
Table 2: Comparison of two risk-category-specific screening intervals with the uniform 5-year screening interval
5-5-5 screening interval* 10-5-2 screening interval* 7-4-1 screening interval*
Number of people at low or intermediate risk at baseline 
(per 1 000 000)
12·4 12·4 12·4
Number of person-years spent unidentified in high-risk category 
(per 1000)
785 (713 to 863) 512 (469 to 559) 282 (254 to 313)
Difference in person-years spent unidentified in high-risk category 
(per 1000)
0 (reference) –273 (–303 to –245) –503 (–550 to –495)
Number of major cardiovascular events prevented 0 (reference) 2730 (2447 to 3033) 5034 (4592 to 5503)
Number of adverse events
Diabetes 0 (reference) 410 (367 to 455) 755 (689 to 825)
Haemorrhagic stroke 0 (reference) 41 (37 to 46) 76 (69 to 83)
Myopathy 0 (reference) 27 (24 to 30) 50 (46 to 55)
Number of QALYs gained 0 (reference) 2475 (2219 to 2750) 4564 (4163 to 4635)
Costs (millions, £)†
Health-check costs 41·3 (40·5 to 42·1) 39·1 (37·9 to 40·3) 63·9 (60·8 to 67·2)
Costs saved due to earlier prevention with statin 0 (reference) –12·9 (–14·4 to –11·6) –23·8 (–26·0 to –21·7)
Total costs (health-check costs – savings) 41·3 (40·5 to 42·1) 26·2 (26·0 to 26·3) 40·0 (39·1 to 41·2)
Total costs compared with 5-5-5 screening interval 0 (reference) –15·1 (–16·1 to –14·2) –1·2 (–1·4 to –0·9)
Figures are estimated for 1 year. QALY=quality-adjusted life-year. *In years for low-risk, intermediate-low-risk, and intermediate-high-risk individuals (95% CI). †In the 
population of England and Wales aged 40–64 years.22 Cost of £18·39 per health check derived from Kypridemos and colleagues19 and costs and QALYs gained with preventive 
statin treatment (£47·33 and 0·00906 QALYs gained per person-year under statin treatment compared with placebo) derived from Collins and colleagues20 and from the 
West of Scotland Coronary Prevention Study.21 The number of adverse events based on incidence estimates of 0·0015, 0·00015, and 0·00010 for diabetes, haemorrhagic 
stroke, and myopathy20 among those who would have received statin treatment.
Table 3: Comparison of two risk-category-specific screening intervals with the uniform 5-year screening interval
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intervals, estimated risk-category-specific screening 
intervals—such as 7-year, 4-year, and 1-year screenings for 
low-risk, intermediate-low-risk, and intermediate-high-
risk individuals, respectively—were estimated to reduce 
time spent unidentified in the high-risk category, to 
prevent major cardiovascular disease events, and to 
increase QALYs by more timely preventive interventions. 
Moreover, our analyses suggest that many protocols with 
screening intervals that are risk-category-specific would 
also reduce health-care costs in England and Wales.
We compared 21 protocols of risk-category-specific 
screening intervals with the uniform 5-year screening 
interval, and our findings provide strong support for 
the benefits of using risk-category-specific screening 
intervals. In terms of QALYs gained and major cardio-
vascular events prevented, all 21 alternative models of 
risk-category-specific screening intervals outperformed 
the 5-year-interval screening; 16 of them were also either 
less costly or the estimated costs did not exceed those 
related to the 5-year screening interval. The lowest esti-
mated costs related to 10-year, 5-year, and 2-year; 8-year, 
4-year, and 2-year; and 9-year, 4-year, and 2-year screening 
intervals for low-risk, intermediate-low-risk, and 
intermediate-high-risk individuals.
Few previous studies have examined cardiovascular 
disease risk progression. Analysis of data from the pre-
statin era derived from the Tokyo Health Check-up study 
and the Framingham study found that among those at 
low risk (as defined by the Framingham General 
Cardiovascular Disease Risk Functions), 9% proceeded 
to the high-risk category within 8 years,25 which is similar 
to our results (appendix p 9). The authors concluded that 
rescreening should be based on baseline risk.25 Our study 
complements these findings by providing specific 
screening intervals that stem from observed risk 
progression and from comparison of different screening 
strategies. Additionally, our study supports earlier study 
findings that suggested more frequent risk factor 
screenings for individuals with higher levels of total 
cholesterol, high systolic blood pressure, or elevated 
glycated haemoglobin.26–28
The performance of the revised ASCVD calculator in 
the present study (C = 0·72) was equally good as in other 
major studies (C = 0·68–0·82).23,29 Despite the high 
discrimination of the cardiova scular risk algorithms, 
their detection rate is modest.30 Thus, in our study, 42% of 
all major cardio vascular disease events occurred among 
individuals at low or intermediate risk based on their 
latest screen in the 5-year screening-interval strategy. 
The corresponding proportion was 34% with the 
7-4-1-year screening strategy. This finding calls for further 
research to identify new biomarkers that would allow 
development of scalable screening instruments with a 
significantly higher detection ratio combined with a low 
false-positive rate.
The strengths of this study include its long follow-up 
and frequent risk-factor measurements according 
to the 5-year-interval guidelines, which enabled 
detailed modelling of 10-year progression of major 
cardiovascular-event risk in an era of modern preventive 
medicine.
The present study also has several limitations. 
Because our findings are from an occupational cohort 
with a higher proportion of men than women, they 
might not apply to the general population, including 
those not in paid employment and to groups that 
are more gender equal. The progression of major 
cardiovascular event risk in the general population 
might be faster than observed in our cohort, indicating 
that more frequent screening might prove optimal in 
such populations. To confirm this theory and to assess 
the generalisability of our findings, further large-scale 
research across different populations and health-care 
systems is essential.
Despite a high response to the survey at the successive 
data-collection phases, loss to follow-up accumulated 
over the extended time period. In our study, the results in 
the main analyses that included missing data and in 
those based on multiple-imputation datasets were 
similar. Multiple imputation assumes that missing 
values can be predicted reasonably accurately with 
variables included in the imputation model, and this is 
thought to justify the missing-at-random assumption. 
Our imputation model included repeated measurements 
of variables that related to missing values and provided 
results similar to those of the complete case analysis, 
thus indicating that major bias due to missing data and 
non-attendance to follow-up examinations is unlikely.
Our estimates of the health benefits from statin 
therapy were based on a microsimulation that took into 
account the effects of low compliance and on the 
WOSCOPS,21 a randomised controlled trial with a 
higher compliance than usually seen in real life; as 
such, the effects of poor compliance on screening 
intervals were only partially addressed in our study and 
these are a potential source of overestimation of the 
benefits of early drug therapies. Conversely, we did not 
consider the additional benefits of an earlier start of 
antihypertensive medication (because this medication 
was part of the risk-score algorithm) or of other 
intensified prevention for high-risk patients, such as 
more professional assistance with lifestyle changes and 
psychosocial risks and a tighter control of obesity and 
dysglycaemia.2 This factor might have contributed to an 
underestimation of the benefits of earlier detection of a 
high-risk state.
A further issue affecting cost-effectiveness of the 
screening intervals, but one impossible to cover in our 
analyses, is that the acceptance and application of new 
guidelines into practice is likely to vary depending 
on the settings in which they are implemented.31 
Ultimately, trials directly comparing the cost-effectiveness 
of different models of screening intervals in various 
health-care systems would address this question.
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In conclusion, this study suggests that a shift from 
5-year-interval screening protocols to risk-category-
specific screening intervals for low-risk, intermediate-
low-risk, and intermediate-high-risk individuals could 
reduce or delay major cardiovascular events, reduce 
health-care costs, and lead to an increase in QALYs 
gained at the population level. Future longitudinal 
studies should examine cardiovascular disease risk 
progression in other cohorts to assess the generalisability 
of our findings and to provide additional evidence to 
guide nationwide cardiovascular disease risk screening 
strategies. If our results are replicated, this would 
support a change from uniform screening intervals to 
ones that are dependent on estimated level of risk.
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